Semiannual Report — FY2026 H1
What Immuno-Biological Laboratories Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31. Filed by 株式会社免疫生物研究所
Filed 2026-11-12View the original on EDINET
How much it says
25Almost nothing
What moved here
4named for the first time
Its own wording
17terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, sales from diagnostic reagent services within the antibody-related business increased, mainly due to factors including continued adoption in clinical trials by overseas CROs, while testing services declined, and consolidated sales increased year on year. Operating income also increased, although impairment losses on investment securities and foreign-exchange losses were recorded, and interim net income attributable to owners of the parent increased.
Komori's summary of this document, not the document's own words.25Almost nothing
How much this filing saysA weighted roll-up of 9 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
52
Typical
0
Almost nothing
23
Almost nothing
75
Very detailed
0
Almost nothing
0
Almost nothing
7
Almost nothing
79
Very detailed
10
Almost nothing
R&D spend59百万円Money spent making new things.
Cash left over-43百万円Cash from the business, less what went into equipment.
Spent on equipment10百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.